Cytogenetic and Flow Cytometric Analysis of : Renal Cell Carcinoma: A Companion Protocol to SWOG-8949
N/A
N/A
Both
Kidney Cancer
Trial Information
Cytogenetic and Flow Cytometric Analysis of : Renal Cell Carcinoma: A Companion Protocol to SWOG-8949
OBJECTIVES:
- Determine if cytogenetic abnormalities can predict clinical outcome, in terms of
response to treatment and survival, in patients with metastatic renal cell carcinoma
registered to the nephrectomy arm (arm I) of SWOG-8949.
- Correlate cytogenetic abnormalities and DNA content analysis (DNA index and S-phase
fraction) with clinical outcome.
OUTLINE: This is a partially prospective, partially retrospective, multicenter, companion
study.
Paraffin-embedded tumor tissue specimens from patients enrolled in SWOG-8949 are evaluated
by cytogenetic analysis (e.g., presence of trisomy and loss of Y chromosome) and flow
cytometric analysis (e.g., presence of nondiploid cells and presence of abnormal
proliferation index).
PROJECTED ACCRUAL: A total of 80 patients will be accrued for this study.
Inclusion Criteria
DISEASE CHARACTERISTICS:
- Diagnosis of renal cell carcinoma
- Any T, any N, M1 disease as specified in SWOG-8949
- Eligible for and registered on the nephrectomy arm* (arm I) of SWOG-8949 NOTE:
*Patients must be registered on this study before undergoing nephrectomy on SWOG-8949
PATIENT CHARACTERISTICS:
- Not specified
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
Type of Study:
Observational
Study Design:
N/A
Outcome Measure:
Number of successes per number of evaluable samples
Safety Issue:
No
Principal Investigator
Robert P. Whitehead, MD
Investigator Role:
Study Chair
Investigator Affiliation:
University of Texas
Authority:
United States: Federal Government
Study ID:
CDR0000502305
NCT ID:
NCT00900042
Start Date:
July 1993
Completion Date:
Related Keywords:
- Kidney Cancer
- stage IV renal cell cancer
- Carcinoma, Renal Cell
- Kidney Neoplasms
Name | Location |
|---|
